NICE Still Skeptical Over Covid 19 Treatments

Pharmaceutical

Five big Covid 19 medicines are not advised to be used according to the UK's National Institute for Health and Care Excellence (NICE).

In England, almost 20,600 reports of positive Covid 19 tests were made from November 5th to November 12th, with over 3,400 were hospitalised with severe Covid 19 at the same time.

“Five big Covid 19 medicines are not advised to be used according to the UK's National Institute for Health and Care Excellence“

A group of organisations wrote a letter to the UK government urging them to support a study proving that those who used Evusheld to prevent the virus had a halved risk of contracting it, and a 92% lower risk of being hospitalised or dying.

The first antibody treatment to be approved by the US FDA for pre-exposure prophylaxis, Evusheld, remains to be a significant part of the Covid therapeutics market.

Regardless of this, NICE is still unsure how the medication would perform in defence of other Covid 19 strains.

The chief executive of NHS England, Amanda Pritchard, emphasised the need to adhere to the NHS cost effectiveness recommendations: “we are continuing to try and make sure that we’re getting the best deals out of the whole medicines budget”.

Following Brexit, the availability of medications in the UK may be less than what it is in the EU. The EU’s efforts to create a European Health Union, to standardise the healthcare systems of all bloc members, have escalated these concerns. This may cause further problems between the European and British pharmaceutical industries.

Pritchard refuted suggestions that the NHS would experience a lack of access to novel medications, claiming “it isn’t unusual now for the NHS to be the first system to have access to new medicines or indeed first in the world and first in Europe deals.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Pharmaceutical
Return to news